Bristol-myers Squibb Compnay

Amarendra B Mikkilineni

Philip Michael Sher

William R Ewing

Natesan Murugesan

Chongqing Sun

Guixue Yu

Annapurna Pendri

Yasutsugu Ueda

Bruce A Ellsworth

Samuel Gerritz

Gang Wu

Yanting Huang

Doree F Sitkoff

Zhengxiang Gu

Ximao Wu

Ying Wang

Ashvinikumar V Gavai

Takayuki Naito

Dolatrai M Vyas

Terrence W Doyle

William N Washburn

Gregory S Bisacchi

Hajime Kamachi

Henry S Wong

Seiji Iimura

Vittorio Farina

Shimpei Aburaki

Kathleen M Poss

Satsuki Okuyama

Arvind Mathur

Stephen R Johnson

Leonard B Crast, Jr

Ravindar N Girotra

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I. including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R, R, R, R, R, m and n are described herein.

Azabicyclic heterocycles as cannabinoid receptor modulators

The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R, R, R, Rand Rare described herein.

Triazolopyrimidine cannabinoid receptor 1 antagonists

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R, R, R, R, R, m and n are described herein.

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formulas I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein B, R, R, Rand x are described herein.

Bicyclic heterocycles as cannabinoind-1 receptor modulators

Compounds of the formula ##STR1## or pharmaceutically acceptable salts thereof wherein: A is a bond, --(CH.sub.2).sub.n -- or --CH(B)--, where n is an integer of 1 to 3 and B is --CN, --CON(R.sup.9)R.sup.9' or --CO.sub.2 R.sup.7 ;

Catecholamine surrogates useful as .beta..sub.3 agonists

The present invention is directed to novel taxol derivatives useful as anti-tumor agents. Also provided by this invention is pharmaceutical formulations and methods of treating mammalian tumors with the compounds of this invention.

Phosphonooxy and carbonate derivatives of taxol

The present invention provides pradimicin analogs which exhibit improved water solubility relative to parent compounds. These novel agents are useful in treatment of fungal infections.

Pradimicin derivatives

Growing community of inventors

Easton, PA, United States of America

Amarendra B Mikkilineni